SLC22A2 and cancer: Research has shown that a specific nonsynonymous single-nucleotide polymorphism (SNP), located in exon 4 of the OCT2 gene (rs316019), is associated with reduced cisplatin-induced nephrotoxicity in Caucasian cancer patients [91, 92]. Consequently, OCT2 has been suggested as a potential target for protective therapeutic approaches against cisplatin-induced nephrotoxicity.